TIDMNSCI
RNS Number : 5166H
NetScientific PLC
18 August 2016
("NetScientific" or the "Company" or the "Group")
Vortex Biosciences Appoints Leading Experts to Newly Formed
Scientific Advisory Board
London, UK - 18 August 2016 - NetScientific plc
("NetScientific", AIM:NSCI), the transatlantic biomedical and
healthcare technology group, announces that its portfolio company
Vortex Biosciences has made a number of appointments to its newly
formed Scientific Advisory Board (SAB).
Commenting on the appointment, NetScientific's Chief Executive
Officer, Francois R. Martelet, said: "This world class Scientific
Advisory Board, chaired by Dr. Massimo Cristofanilli, will play a
crucial role providing strategic and clinical guidance to Vortex
Biosciences as the Company's circulating tumor cell enrichment
system, the VTX-1, moves towards commercialisation."
Vortex Bioscience's press release follows:
Vortex Biosciences Appoints Leading Experts to Newly Formed
Scientific Advisory Board
Distinguished Clinicians and Bioengineers to Provide Perspective
on Research and Development of Next Generation Circulating Tumor
Cell Enrichment System
MENLO PARK, CA, August 18, 2016 - Vortex Biosciences, provider
of circulating tumor cell (CTC) enrichment systems, today announced
the appointment of leading experts to its newly formed Scientific
Advisory Board (SAB). The SAB's mission will be to provide valuable
scientific and clinical insights, along with strategic guidance in
decision-making to support the development and commercialization of
Vortex's CTC enrichment system for both the research and diagnostic
markets.
The members of Vortex Bioscience's SAB include:
-- Massimo Cristofanilli, M.D., Associate Director for
Translational Research and Precision Medicine and Professor of
Medicine in the Division of Hematology & Oncology at the Robert
H Lurie Comprehensive Cancer Center, Northwestern
University-Feinberg School of Medicine.
-- Jonathan Goldman, Director of Clinical Trials in Thoracic
Oncology and the Associate Director of Drug Development at UCLA
Health;
-- Stanley Frankel, M.D., Corporate Vice President, Head,
Immuno-oncology Clinical Research & Development, Celgene;
and
-- Dino Di Carlo, Ph. D., Director, Cancer Nanotechnology
Program Jonsson Comprehensive Cancer Center and Professor in the
Department of Bioengineering, UCLA.
"We are thrilled to have attracted some of the world's leading
experts in circulating tumor cells, oncology, clinical trials and
microfluidics to help us define our clinical strategy as we
commercialize our next generation CTC enrichment system, the
VTX-1," said Gene Walther, Chief Executive Officer of Vortex
Biosciences "The formation of our SAB serves as an endorsement of
the scientific and clinical enthusiasm for the Vortex
technology."
Vortex Biosciences Scientific Advisory Board members:
Massimo Cristofanilli, MD, an expert in the translational
research and treatment of patients with inflammatory breast cancer
(IBC), is the Associate Director for Translational Research and
Precision Medicine and Professor of Medicine in the Division of
Hematology & Oncology at the Robert H Lurie Comprehensive
Cancer Center, Northwestern University-Feinberg School of Medicine.
Dr. Cristofanilli has led the development of novel diagnostic and
prognostic markers in primary and metastatic breast cancer. His
paper in the New England Journal of Medicine opened up the liquid
biopsy field showing the prognostic importance of CTCs in breast
cancer with the CellSearch system. In his research and academic
role he is focused on advancing a patient-centered, biology driven
model of cancer care; combining sophisticated tissue and
blood-based molecular diagnostic technologies and innovative
treatments. Prior to joining the Lurie Cancer Center, Dr.
Cristofanilli was Director of the Breast Care Center and Deputy
Director for Translational Research at the Sidney Kimmel Cancer
Center at Thomas Jefferson University. He previously served as
Chair of the Department of Medical Oncology at Fox Chase Cancer
Center, and Executive Director of the Morgan Welch Inflammatory
Breast Cancer Program and Clinic at the University of Texas MD
Anderson Cancer Center.
Stanley Frankel, M.D., is an internationally recognized expert
in the treatment of hematologic malignancies including ALL and
lymphoma. He is currently the Corporate Vice President, Head of
Immuno-oncology, Clinical Research and Development at Celgene.
Through 2014 he served as Executive Director, Medical Sciences;
Early Development, Oncology Therapeutic Area Head at Amgen. Among
his primary responsibilities at Amgen were the clinical development
of bispecific T cell engaging antibody constructs (BiTE(R)s)
including blinatumomab. Prior experience includes roles as Vice
President, Clinical Develoment at Micromet, Clinical Director and
Clinical Science Leader at Hoffman-LaRoche; Executive Director for
US External Scientific Affairs and Senior Director, Clinical
Research at Merck. Dr. Frankel chaired the Zolinza Product
Development Team and led the clinical efforts for the successful
approval of Zolinza in 2006. From 2001-2004, he was Director,
Medical Operations, at Genta, Inc working on Genasense. Prior to
joining Genta, Dr. Frankel was Clinical Associate Professor of
Medicine at the University of Maryland in Baltimore Greenebaum
Cancer Center. He was previously on the faculty at Roswell Park
Cancer Institute in Buffalo, NY and the Lombardi Cancer Center at
Georgetown University. In addition to his contributions to the
approval of Blincyto and Zolinza, Dr. Frankel worked as an academic
investigator on the development of 11 other approved oncology drugs
including Vesanoid and Trisenox for acute promyelocytic leukemia,
Rituxan, Zevalin, Bexxar for CD20 expressing malignancies,
Neulasta, Kepivance, Mylotarg, and Gleevec.
Jonathan Goldman, M.D., is the Director of Clinical Trials in
Thoracic Oncology and the Associate Director of Drug Development at
UCLA Health. He completed his residency at UCSF and his fellowship
in Hematology/Oncology at UCLA. His research focuses on cancer drug
development with an emphasis on treatment for thoracic
malignancies. In his role as the Director of Clinical Trials, he is
working to develop novel anti-cancer drugs that have been
identified in the lab and investigate their toxicity and efficacy
with patients in the clinic. Most recently he has been conducting
trials that look at the effect of combination therapies of EGFR
inhibitors like Rociletinib and PDL-1 inhibitors like Atezolizumab
in EGFR-mutant NSCLC. Clinically, he cares for patients with many
types of cancer, with a particular focus on treating lung cancer.
He is always looking for new approaches to improve the efficiency
of clinical trials. In collaboration with other departments, he has
developed novel laboratory and radiographic techniques to aid in
both patient stratification and patient monitoring. He received his
degree from Harvard University and his M.D. from Stanford Medical
School.
Dino Di Carlo has been on the faculty in the Department of
Bioengineering at UCLA since 2008 where he pioneered using inertial
fluid dynamic effects for the control, separation, and analysis of
cells in microfluidic devices. He is currently Director of the
Cancer Nanotechnology Program at the Jonsson Comprehensive Cancer
Center and a Professor in the Department of Bioengineering at the
University of California, Los Angeles (UCLA). He directs the
Microfluidic Biotechnology Laboratory with work that extends into
numerous fields of biomedicine and biotechnology including cell
separation and analysis, directed evolution, nano-magnetic cell
analysis and control, new amplified molecular assays, next
generation biomaterials, and phenotypic drug screening. Among other
honors he received the Presidential Early Career Award for
Scientists and Engineers (PECASE) was elected a Fellow the American
Institute for Medical and Biological Engineering (AIMBE) and of the
Royal Society of Chemistry (FRSC). He also has been honored by
academic societies across a range of fields with the Pioneers of
Miniaturization Prize, the Materials Research Society (MRS)
Outstanding Young Investigator Award and the Analytical Chemistry
Young Innovator Award. He was awarded the National Science
Foundation (NSF) Faculty Early Career Development award, the U.S.
Office of Naval Research (ONR) Young Investigator Award, and the
Packard Fellowship. His translational research was also supported
by the Defense Advanced Research Projects Agency (DARPA) Young
Faculty Award, the National Institutes of Health (NIH) Director's
New Innovator Award and Coulter Translational Research Award.
About Vortex Biosciences
Vortex Biosciences is a cancer research and diagnostics company
that integrates cancer biology, microfluidic engineering and
informatics to develop tools for isolating and characterizing
circulating tumor cells. The Vortex VTX-1 instrument harvests
intact circulating tumor cells from whole blood samples for use in
downstream research and clinical applications such as patient
stratification in clinical trials, monitoring disease progression
and drug treatment effectiveness. With a mission to enable
noninvasive diagnosis of cancer and real-time monitoring throughout
a patient's treatment, Vortex is at the forefront of accelerating
cancer research and improving patient outcomes. Vortex is a core
subsidiary of NetScientific plc, a transatlantic healthcare
technology group with an investment strategy focused on sourcing,
funding and commercializing technologies that significantly improve
the health and well-being of people with chronic diseases. For more
information, visit www.vortexbiosciences.com.
- Ends -
For more information, please contact:
NetScientific Tel: +44 (0)20 3514
François R. Martelet, 1800
M.D., CEO
Ian Postlethwaite, CFO
Stifel Nicolaus Europe Limited Tel: +44 (0) 20 7710
(NOMAD and broker) 7600
Jonathan Senior / David
Arch / Ben Maddison
Consilium Strategic Communications Tel: +44 (0)20 3709
Mary-Jane Elliott / Chris 5700
Gardner / Jessica Hodgson netscientific@consilium-comms.com
/ Chris Welsh / Laura Thornton
About NetScientific Plc
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSFESMAFMSESA
(END) Dow Jones Newswires
August 18, 2016 02:06 ET (06:06 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024